查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1067061

細胞化驗分析市場:規模，佔有率，趨勢分析:各產品、服務，各類型，各終端用戶，各地區預測，競爭策略，至2030年的各市場區隔預測

Cell-based Assays Market Size, Share & Trends Analysis By Product & Service, By Type, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球細胞化驗分析的市場規模，預計今後以7.4％的年複合成長率擴大，至2030年達到304億美元。

本報告提供全球細胞化驗分析市場相關調查，市場概要，以及產品、各服務，各類型，各終端用戶，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長要素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • COVID-19細胞化驗分析市場的影響

第5章 市場變數及預測

  • SWOT分析
    • 優勢
    • 弱點
    • 市的場機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術性形勢
    • 環境的形勢
    • 法律上的形勢
  • 波特的五力分析
    • 賣主談判力
    • 買方議價能力
    • 替代威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球細胞化驗分析市場，各產品、服務，2019年～2030年(100萬美元)

  • 消耗品
  • 細胞株
  • 微孔盤
  • 探針和標籤
  • 其他的消耗品
  • 設備和軟體
  • 服務

第7章 全球細胞化驗分析市場，各類型，2019年～2030年(100萬美元)

  • 藥物研發
  • 基礎研究
  • 其他

第8章 全球細胞化驗分析市場，各終端用戶，2019年～2030年(100萬美元)

  • 製藥公司及生物醫藥品企業
  • CRO
  • 研究學術機構

第9章 全球細胞化驗分析市場，各地區，2019年～2030年(100萬美元)

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他

第10章 企業簡介

  • AAT Bioquest
  • Becton, Dickinson and Company
  • BioAgilytix Labs
  • Charles River Laboratories
  • Danaher Corporation
  • Lonza
  • Merck KGaA
  • PerkinElmer, Inc
  • Promega Corporation
  • Reaction Biology Corporation
  • Thermo Fisher Scientific
簡介目錄
Product Code: BIOT2209

Global cell-based assays market is projected to be worth USD 30.4 billion by 2030

According to SPER Market Research, the cell-based assays market is estimated to reach USD 30.4 billion by 2030 with a CAGR of 7.4%. Rising prevalence of infectious diseases and risk of pandemics has propelled research and development for vaccines and novel drug developments. Cell-based assays are used in drug development processes to improve reliability, efficiency and decrease lead time.

Impact of COVID-19 on the Cell-based Assays Market

COVID-19 has increased the burden on healthcare industry. R&D activities have scaled up to meet the urgent need of vaccines and drugs against COVID-19. The funding and investments in research have also been increased due to which research activities were unaffected in operations during the pandemic. Small and large players of this market are aligning their goals towards research market to tap the opportunities. Thus, manufacturing of cell-based assays is also growing at a significant rate. Cell-based assays provide early detection with more accuracy due to which it is more preferred as compared to other conventional assays.

Scope of the report:

Market size available for years

2019-2030

Base year considered

2021

Forecast period

2022-2030

Segments covered

By Product & Service, By Type, By End User

Geographies covered

North America, Europe, APAC, Latin America and the Middle East & Africa

Companies Covered

AAT Bioquest, Becton, Dickinson and Company, BioAgilytix Labs, Charles River Laboratories, Danaher Corporation, Lonza, Merck KGaA, PerkinElmer, Inc., Promega Corporation, Reaction Biology Corporation, Thermo Fisher Scientific

Driver: Adoption of Cell-based assays for discovery of drugs

The cell-based assays offer many advantages as compared to biochemical assays such as consistent tissue-specific responses, greater efficiency, cost effectiveness and shorter lead time. Therefore, many pharmaceutical and biotechnology companies are adopting cell-based assays in place of biochemical assays for drug discovery. Cell-based assays can be used for lead identification and optimization in drug discovery process.

Restraints: High instrument cost

The technologies of high-throughput screening and high-content screening are highly costly. The cost of these technologies can increase with an increase in the complexity of a molecule to be assayed. Academic institutions can't afford to own these technologies for research due to budget constraints. In biopharmaceutical companies, cost of production increases significantly due to the adoption of such systems, maintenance charges and indirect costs.

Opportunity: Emerging markets in Asia

Asian countries such as India, China are economically emerging countries which offer significant growth opportunities to cell-based assays market. The labor and raw material cost is comparatively cheaper in these countries. The pandemic risk is also higher due to large population. Moreover, supportive government initiatives, rising focus on life science research and increasing R&D funding also attracts small and large players of cell-based assays market to these countries.

Challenge: Restrictions on reagents usage

There are many factors that restrict the growth of reagents in cell-based assays market. Product end-user license restricts the usage of reagents for specific assays only. In such case, the better reagents available in the market are not adopted even when they are of superior quality. This can pose a challenge to the growth of this market in reagents segment.

Cell-based Assays Market by Product & Service:

Based on product & service, market has been segmented into Consumables (Reagents, Assay Kits [Reporter Gene Assays, Cell Growth Assays, Second Messenger Assays, Cell Death Assays, Other Assay Kits], Cell Lines [Immortalized Cell Lines, Primary Cell Lines, Stem Cell Lines]), Microplates, Probes & Labels, Other Consumables, Instruments & Software, Services

Cell-based Assays Market by Type:

Based on type, the market is segmented into Drug Discovery (Toxicity Studies, Pharmacodynamic Studies, Pharmacokinetic Studies), Basic Research, Other Application

Cell-based Assays Market by End User:

Based on end user, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, CROs, Research & Academic Institutes

Pharmaceutical & Biopharmaceutical companies have the largest share of this market by end user due to high R&D expenditure, increasing number of projects in drug discovery and collaborations & partnerships between companies and

Cell-based Assays Market by Region:

North America owns the largest share of this market owing to supportive government initiatives, rising funding in research, increasing penetration of CRPs and high adoption of advanced technologies.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary data
    • 2.1.2. Primary data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impact of the Cell-based Assays Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL analysis
    • 5.2.1. Political landscape
    • 5.2.2. Economic landscape
    • 5.2.3. Social landscape
    • 5.2.4. Technological landscape
    • 5.2.5. Environmental landscape
    • 5.2.6. Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of Buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cell-based Assays Market, By Product and Service, 2019-2030 (USD Million)

  • 6.1. Consumables
    • 6.1.1. Reagents
    • 6.1.2. Assay Kits
      • 6.1.2.1. Reporter Gene Assays
      • 6.1.2.2. Cell Growth Assays
      • 6.1.2.3. Second Messenger Assays
      • 6.1.2.4. Cell Death Assays
      • 6.1.2.5. Other Assay Kits
  • 6.2. Cell Lines
    • 6.2.1. Immortalized Cell Lines
    • 6.2.2. Primary Cell Lines
    • 6.2.3. Stem Cell Lines
  • 6.3. Microplates
  • 6.4. Probes & Labels
  • 6.5. Other Consumables
  • 6.6. Instruments & Software
  • 6.7. Services

7. Global Cell-based Assays Market, By Type, 2019-2030 (USD Million)

  • 7.1. Drug Discovery
    • 7.1.1. Toxicity Studies
    • 7.1.2. Pharmacodynamic Studies
    • 7.1.3. Pharmacokinetic Studies
  • 7.2. Basic Research
  • 7.3. Other Application

8. Global Cell-based Assays Market, By End User, 2019-2030 (USD Million)

  • 8.1. Pharmaceutical & Biopharmaceutical Companies
  • 8.2. CROs
  • 8.3. Research & Academic Institutes

9. Global Cell-based Assays Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AAT Bioquest
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Becton, Dickinson and Company
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. BioAgilytix Labs
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Charles River Laboratories
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Danaher Corporation
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Lonza
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Merck KGaA
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. PerkinElmer, Inc.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Promega Corporation
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Reaction Biology Corporation
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Thermo Fisher Scientific
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments